Table 2.

Teriflunomide: factors potentially influencing patient preference in MS

Efficacy	Comparable to interferon beta-1a sc tiw in the TENERE study6
Route of administration	Oral
Dosing frequency	Once daily
Half-life	19 days (median)
Pharmacovigilance	Initially frequent liver enzyme controls (every 2 weeks)
Side effects (selection only)	Arterial hypertension Gastrointestinal disorders (diarrhea, nausea) Hair thinning Hematological abnormalities (leucopenia, lymphopenia) Liver enzyme increase

Abbreviations: MS, multiple sclerosis; sc, subcutaneous; TENERE, TErifluNomidE and REbif.^®; tiw, three times weekly.